These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 27355333)

  • 1. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
    Clark O; Yen K; Mellinghoff IK
    Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enasidenib and ivosidenib in AML.
    Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
    Lee S; Urman A; Desai P
    Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
    Waitkus MS; Diplas BH; Yan H
    Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.
    Ivanov S; Nano O; Hana C; Bonano-Rios A; Hussein A
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
    Chen J; Yang J; Cao P
    Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
    Liu S; Cadoux-Hudson T; Schofield CJ
    Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
    van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
    Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.